Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

Enlivex Anuncia Colocação Privada de US $212.000.000 para Início da Primeira Estratégia de Previsão de Mercados de Tesouro de Ativos Digitais do Mundo, via Acumulação de tokens RAIN, e a Nomeação de Matteo Renzi, Ex-Primeiro-Ministro da Itália, para seu Conselho

- Após o fechamento da colocação privada, a Enlivex adotará a primeira estratégia de tesouro de ativos digitais de token de previsão RAIN do mundo, por meio do acúmulo de token RAIN. - RAIN é um...
November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

Enlivex anuncia una colocación privada de $212,000,000 para iniciar la primera estrategia de tesorería de activos digitales basada en mercados de predicción en el mundo, mediante la acumulación del token RAIN, y el nombramiento de Matteo Renzi, ex Primer Ministro de Italia, como miembro de su directorio.

- Tras el cierre de la colocación privada, Enlivex adoptará la primera estrategia de tesorería de activos digitales basada en mercados de predicción del mundo, mediante la acumulación del token RAIN. ...
November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

Enlivex annonce un placement privé de 212 000 000 $ pour lancer la première stratégie au monde de trésorerie d’actifs numériques sur les marchés prédictifs, via l’accumulation de jetons RAIN, et la nomination de Matteo Renzi, ancien Premier ministre italien, à son conseil d’administration

- À la clôture du placement privé, Enlivex adoptera la première stratégie au monde de trésorerie d’actifs numériques sur les marchés prédictifs RAIN, via l’accumulation de jetons RAIN. - RAIN est un...
November 24, 2025 07:55 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully...
November 24, 2025 06:40 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
October 28, 2025 08:15 ET | Source: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
September 29, 2025 08:15 ET | Source: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a...
September 11, 2025 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected...
September 09, 2025 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
August 18, 2025 07:45 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee...